drugset / Trial / NCT01032941

The Effect of Probiotics (VSL) on Portal Hypertension

NCT01032941

Phase 1/2 Completed 18 enrolled University of Alberta
RandomizedParallel-groupTriple-blindHealth-services research

Summary

The investigators will address the hypothesis that portal hypertension is mediated in part by bacterial or endotoxin translocation and the production of inflammatory mediators (tumor necrosis factor-α (TNFα), etc.). The investigators hypothesize that food supplementation with the probiotic product VSL#3 in patients with Child Pugh B/C cirrhosis will have a beneficial effect on in portal pressure (as measured by the HVPG) by reducing inflammatory mediators and improving systemic and splanchnic hemodynamics.

Timeline

Start
2009-12
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VSL#3 Other / unclassified 2 unknown

Indications